Tracking Heart Failure Drug Treatment Against Current Guidelines in Patients
Records how heart failure patients are treated and whether they follow current guideline medicines.
Plain-language title generated from the registry record
Registry title: Drug Management in Heart Failure
Key facts
- Where
- Rome, ItalySee the site
Where in Italy
- IRCCS San RaffaeleRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS San Raffaele Roma
- Trial code
- NCT06915584
- Record updated
- 20 October 2026
- Original description
Aim of the proposal is to create an interactive AI-based multicentre prospective database to provide information on how to improve the QoC for pts with HF.This will provide detailed information on pts characteristics,treatment practices, adherence to prescribed guideline-based optimal drug therapy,and outcomes.The database stems from a registry started two years ago,conceived to provide a contemporary snapshot on the adherence to the latest European GGLL for the therapeutic management of pts with HF.The database will be integrated with a specifically designed algorithm that provides an accurate feedback on whether patients are properly treated according to the ESC most recent recommendations.The expected outcomes are:-define non-adherence level to GGLL-based recommendations for treatment of HF;-provide information on initiation, adherence and persistence over time of the recommended treatment;-reduce medical inertia;produce practical implications to reduce morbidity and mortalityRead full original descriptionShow less
Drug Management in Heart Failure
Aim of the proposal is to create an interactive AI-based multicentre prospective database to provide information on how to improve the QoC for pts with HF.This will provide detailed information on pts characteristics,treatment practices, adherence to prescribed guideline-based optimal drug therapy,and outcomes.The database stems from a registry started two years ago,conceived to provide a contemporary snapshot on the adherence to the latest European GGLL for the therapeutic management of pts with HF.The database will be integrated with a specifically designed algorithm that provides an accurate feedback on whether patients are properly treated according to the ESC most recent recommendations.The expected outcomes are:-define non-adherence level to GGLL-based recommendations for treatment of HF;-provide information on initiation, adherence and persistence over time of the recommended treatment;-reduce medical inertia;produce practical implications to reduce morbidity and mortality
Inclusion: Both gender; Age >18 years; Signed informed consent for the study; Known diagnosis of heart failure > 6 months; Recent or ongoing hospitalization for heart failure exacerbation.
Exclusion: Concurrent diagnosis of neoplasia; Conditions that, in the investigator's judgment, may interfere with the study or contraindicate participation for safety reasons; Advanced valvular heart disease (severe mitral-aortic stenosis-insufficiency requiring cardiac surgery); Advanced COPD (FEV1 <50%).